AliveDx Suisse S.A. is pleased to announce the signing of a strategic distribution agreement with Ilex Medical. Under this agreement, Ilex Medical is authorized to distribute AliveDx’s MosaiQ® and LumiQ® solutions in Israel. This partnership represents another important milestone in
AliveDx Suisse S.A. is pleased to announce the signing of a strategic distribution agreement with Hospital Supply Corporation (HSC), Pakistan. Under this agreement, HSC is authorized to distribute AliveDx’s MosaiQ® and LumiQ® solutions across Pakistan. This partnership represents an important milestone in AliveDx’s expansion in South Asia and
AliveDx Suisse S.A. is pleased to announce the signing of a strategic distribution agreement with Reacting Sarl. Under this agreement, Reacting Sarl is authorized to distribute AliveDx’s MosaiQ® and LumiQ® solutions across Morocco. This partnership represents a further step in
AliveDx Suisse S.A. is pleased to announce the signing of a strategic distribution agreement with Address Medical. Under this agreement, Address Medical is authorized to distribute AliveDx’s MosaiQ® and LumiQ® solutions in United Arab Emirates. This partnership represents another important
AliveDx Suisse S.A. and DPC Lebanon (Diagnostic Products Corporation Lebanon Sarl) Sign Strategic Distribution Agreement in Lebanon AliveDx Suisse S.A. is pleased to announce the signing of a strategic distribution agreement with DPC Lebanon. Under this agreement, DPC Lebanon is
AliveDx is proud to announce that we have successfully completed the 2025/26 NHS Evergreen Sustainable Supplier Assessment, achieving Level 2 status in the UK. This annual assessment is a key benchmark for suppliers to the NHS in the UK, measuring
Manuel Ó. Méndez Muñiz Chairman and CEO
Manuel O. Méndez, Chairman and Chief Executive Officer, joined AliveDx in April 2021, bringing over thirty years of experience in the diagnostic and life science markets
Mr. Méndez came to AliveDx from Quest Diagnostics Incorporated (NYSE: DGX), a leading global provider of diagnostic information services, where he served as Senior Vice President and Chief Commercial Officer and played a key role in accelerating growth and supporting efforts related to COVID-19. In earlier years, Mr. Méndez held various executive and senior leadership roles in the in-vitro diagnostic industry at QIAGEN, Abbott Laboratories, Thermo Fisher Scientific, OraSure Technologies and bioMerieux, including Senior Vice President, Global Commercial Operations, Chief Commercial Officer and member of the Executive Committee.
Mr. Méndez earned a Master of Business Administration degree from Northwestern University’s Kellogg School of Management and a Bachelor’s degree in biomedical engineering from Boston University.
Bradley C. Meyer Lead Independent Manager
Bradley C. Meyer, is Lead Independent Manager and member of AliveDx Board of Managers, since February 2023, bringing over two decades dedicated to financial advisory and restructuring including in health technology.
Mr. Meyer is a founding partner and senior advisor at Ducera Partners, and a founding member of Millstein & Co.. He previously held senior roles at Perella Weinberg Partners, Houlihan Lokey, and Lazard, focusing on mergers and acquisitions and financial restructuring. In addition to serving on AliveDx’s board, he also serves on the boards of Aveng Group and Biocartis SA.
Mr. Meyer earned a Bachelor of Arts in Economics from Harvard University.
David W. Bryant Independent Manager
David W. Bryant is a member of AliveDx Board of Managers since April 2023, bringing over thirty-five years of executive experience in the life sciences and diagnostics sectors.
Mr. Bryant also served as Group Senior Vice President over Eurofins North American Portfolio of Food, Feed and Agriculture Labs and served on the Group Operating Counsel for Eurofins Globally. Prior to that, Mr. Bryant was Chief Executive Officer of Sonic Healthcare USA, and founded, chaired, and led SeLux Diagnostics, focused on molecular diagnostics. Mr. Bryant also sat on the Board of American Pathology Partners.
Mr. Bryant earned a Bachelor of Science in Economics at North Carolina State University and served as a Major in the US Marine Corps.
Roger Moody Independent Manager
John Roger Moody, Jr. is a member of AliveDx Board of Managers since November 2025, bringing over 25 years of executive experience in the medical technology, diagnostics and life sciences sectors.
Mr. Moody is the Chief Executive Officer of Biocartis, having previously served as Chief Executive Officer of GlySure Limited, now owned by Baxter International (NYSE: BAX). Previously, Mr. Moody held senior financial leadership positions, including Chief Financial Officer roles at Nanosphere (now part of DiaSorin (Euronext Milan: DIA)), Clinical Genomics, Inc., and most recently Talis Biomedical (Nasdaq: TLIS). Mr. Moody began his career at IBM, where he supported the formation and rapid expansion of IBM Global Services through a range of strategic and operational roles.
Mr. Moody earned a Bachelor of Science degree in Finance from Syracuse University and an MBA from the University of Chicago Booth School of Business.
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.